NCT03343054View on ClinicalTrials.gov

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 30, 2017

Primary Completion Date

January 11, 2021

Study Completion Date

July 18, 2024

Conditions
NeoplasmsBreast Neoplasms
Interventions
DRUG

talazoparib

Talazoparib will be administered orally on a continuous basis. Talazoparib may be taken with or without food. Each cycle will consist of 28 days.

Trial Locations (8)

464-8681

Aichi Cancer Center Hospital, Nagoya

277-8577

National Cancer Center Hospital East, Kashiwa

003-0804

National Hospital Organization Hokkaido Cancer Center, Sapporo

241-8515

Kanagawa Cancer Center, Yokohama

362-0806

Saitama Cancer Center, Kitaadachi-gun

104-0045

National Cancer Center Hospital, Chuo-Ku

892-0833

Hakuaikai Medical Corporation Sagara Hospital, Kagoshima

540-0006

National Hospital Organization Osaka National Hospital, Osaka

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03343054 - A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter